Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
2.500
+0.110 (4.60%)
At close: Dec 24, 2024, 1:00 PM
2.410
-0.090 (-3.60%)
After-hours: Dec 24, 2024, 4:37 PM EST
Sangamo Therapeutics Revenue
Sangamo Therapeutics had revenue of $49.41M in the quarter ending September 30, 2024, with 425.77% growth. This brings the company's revenue in the last twelve months to $52.29M, down -74.04% year-over-year. In the year 2023, Sangamo Therapeutics had annual revenue of $176.23M with 58.34% growth.
Revenue (ttm)
$52.29M
Revenue Growth
-74.04%
P/S Ratio
9.25
Revenue / Employee
$129,114
Employees
405
Market Cap
521.62M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 176.23M | 64.93M | 58.34% |
Dec 31, 2022 | 111.30M | 598.00K | 0.54% |
Dec 31, 2021 | 110.70M | -7.49M | -6.34% |
Dec 31, 2020 | 118.19M | 15.76M | 15.39% |
Dec 31, 2019 | 102.43M | 17.98M | 21.29% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Auna S.A. | 1.17B |
Xeris Biopharma Holdings | 187.36M |
Talkspace | 181.29M |
Semler Scientific | 58.94M |
EyePoint Pharmaceuticals | 45.71M |
Phathom Pharmaceuticals | 26.27M |
CorMedix | 12.26M |
Mereo BioPharma Group | 1.00M |
SGMO News
- 5 days ago - Sangamo: Pipeline Expansion Via Partnership And Internal ST-503 Development - Seeking Alpha
- 6 days ago - Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases - PRNewsWire
- 5 weeks ago - Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain - Business Wire
- 6 weeks ago - Sangamo Therapeutics, Inc. (SGMO) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results - Business Wire
- 7 weeks ago - Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast - Business Wire
- 2 months ago - Sangamo: Fabry Disease Gene Therapy Moves Forward With Positive FDA Regulatory Development - Seeking Alpha
- 2 months ago - Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 - Business Wire